# Acadia Pharmaceuticals Reports $342 Million in Quarterly Revenue and Raises Full-Year Guidance

> Acadia Pharmaceuticals reported $342 million in quarterly revenue, with DAYBUE at $140 million and NUPLAZID at $202 million.

- Published: 2026-11-17T18:28:17+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-17/acadia-pharmaceuticals-quarterly-revenue-guidance
- Source: [Seeking Alpha](https://seekingalpha.com/article/4969070-acadia-pharmaceuticals-inc-acad-presents-at-ubs-global-biopharma-conference-2026-transcript?source=feed_all_articles)

## Key takeaways

- Acadia Pharmaceuticals reported quarterly revenue of $342 million, up 22% year-over-year.
- DAYBUE net sales reached $140 million, up 39%, and NUPLAZID net sales reached $202 million, up 12%.
- Acadia raised its full-year guidance to between $505 million and $520 million.
- The company received weight-banded dosing approval for DAYBUE, extending U.S. protection to 2041.

[Acadia Pharmaceuticals](https://akta.pro/company-profiles/0000pk5/acadia-pharmaceuticals-inc) reported quarterly revenue of $342 million, up 22% year-over-year, and raised its full-year guidance to between $505 million and $520 million, CEO Catherine Owen Adams said at the UBS Global Biopharma Conference 2026 on November 17, 2026, according to a [Seeking Alpha](https://seekingalpha.com/article/4969070-acadia-pharmaceuticals-inc-acad-presents-at-ubs-global-biopharma-conference-2026-transcript?source=feed_all_articles) transcript. Acadia is a San Diego-based biopharmaceutical company that develops and commercializes therapies for central nervous system disorders, including Rett syndrome and Parkinson's disease psychosis.

## Acadia's DAYBUE and NUPLAZID Sales Growth

DAYBUE net sales were $140 million in the quarter, up 39% year-over-year, and NUPLAZID net sales were $202 million, up 12%, Owen Adams said. She said most of the NUPLAZID growth came from volume. The company also received weight-banded dosing approval for DAYBUE, which Owen Adams said extends U.S. protection to 2041, an additional five years, and Acadia is pursuing the same protection in Europe. Owen Adams said Acadia has more than $970 million on its balance sheet and will focus that effort on business development spending. "So as a company, we delivered $342 million, which was a 22% year-over-year growth against both the brands that you just talked about," she said.

## Acadia's Revenue and Funding Records

According to akta.pro [company records](https://akta.pro/company-data), Acadia reported full-year 2025 GAAP total revenues of $1.07 billion, up 12% year-over-year and the first time the company surpassed $1 billion in annual revenue. The company reaffirmed 2026 revenue guidance of $1.22 billion to $1.28 billion. Acadia's total funding stands at $811.7 million, with the last round a 2019-09 post-IPO equity raise of $287.5 million, the same records show.

## Acadia's Earlier Deals and Trial Data

In November 2026, Acadia presented Phase 2 RADIANT trial data for remlifanserin in Alzheimer's disease psychosis at CTAD 2026, with the 60 mg once-daily dose showing a consistent efficacy signal and 44% of patients improved versus 31.8% on placebo at Week 6, [Stock Titan](https://akta.pro/news-signals) reported. Acadia also entered an exclusive distribution agreement with KYORIN Pharmaceutical to commercialize DAYBUE STIX for Rett syndrome in Japan, with a $30 million upfront payment, Stock Titan reported. Earlier in November 2026, Acadia said it expects a Federal Circuit decision in the first half of 2027 on its NUPLAZID formulation patent appeal, with protection extending to February 2038 if upheld or October 2030 otherwise, Stock Titan reported.

## Acadia's Patent Appeal Decision

Acadia expects the Federal Circuit to rule on its NUPLAZID formulation patent appeal in the first half of 2027, a decision that will determine whether patent protection runs to February 2038 or October 2030.

## Companies in this story

- [Acadia Pharmaceuticals Inc. company profile](https://akta.pro/company-profiles/0000pk5/acadia-pharmaceuticals-inc) · website: https://www.acadia-pharm.com

---
News for Agent · https://newsforagent.com/llms.txt
